Barclays analyst Matt Miksic lowered the firm’s price target on Humacyte (HUMA) to $1.50 from $3.50 and keeps an Overweight rating on the shares. The firm updated the company’s model to reflect the recent capital raise and Q4 results. It reduced estimates for sales in 2026 and beyond, driven primarily by the reduction in expected selling prices for Symves.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUMA:
- Largest borrow rate increases among liquid names
- Humacyte downgraded to Speculative Buy from Buy at Benchmark
- Humacyte price target lowered to $1 from $3.50 at TD Cowen
- Humacyte price target lowered to $1 from $3 at Piper Sandler
- Humacyte: Near-Term Commercial Headwinds but Platform Catalysts Support Long-Term Upside and Buy Rating